This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Al-InanyHG,YoussefMA,AboulgharM,BroekmansF,SterrenburgM,SmitJ,Abou-SettaAM(2011):Gonadotrophin-releasinghormoneantagonistsforassistedreproductivetechnology.CochraneDatabaseSystRev.2011May11;(5):CD001750AndrejakM,TribouilloyC(2013):Drug-inducedvalvularheartdisease:anupdate.ArchCardio-vascDis106:333–339
ChoiJ,SmitzJ(2014):Luteinizinghormoneandhumanchorionicgonadotropin:originsofdifference.MolCellEndocrinol383:203–213
deMouzonJ,AllavenaE,SchmittC,FrappeM(2004):InvitrofertilizationinFrance:economicaspectsandinfluenceofthegonadotropinchoice(urinaryvs.recombinant)oncost.GynecolObstetFertil32:508-518.[ArticleinFrench]
FleseriuM(2011):Clinicalefficacyandsafetyresultsfordoseescalationofsomatostatinrecep-torligandsinpatientswithacromegaly:aLiteraturereview.Pituitary14:184–193
InternationalRecombinantHumanChorionicGonadotropinStudyGroup(2001):InductionofovulationinWorldHealthOrganizationgroupIIanovulatorywomenundergoingfollicularstimulationwithrecombinanthumanfollicle-stimulatinghormone:acomparisonofrecombinanthumanchorionicgonadotropin(rhCG)andurinaryhCG.FertilSteril75:1111–1118
LiuH,BravataDM,OlkinI,NayakS,RobertsB,GarberAM,HoffmanAR(2007):Systematicreview:thesafetyandefficacyofgrowthhormoneinthehealthyelderly.AnnInternMed146:104–115
MelmedS(2006):Acromegaly.NEnglJMed355:2558–2573
NationalInstituteforHealthandCareExcellence(2010):Humangrowthhormone(somatropin)forthetreatmentofgrowthfailureinchildren.NICEtechnologyappraisalguidance188.Internet:http://www.nice.org.uk/guidance/ta188/resources/guidance-human-growth-hormone-somatropin-for-the-treatment-of-growth-failure-in-children.pdf
National Institute for Health and Care Excellence (NICE) (2003): Human growth hormone (somatropin) in adults with growth hormone deficiency. Technology Appraisal 64. Internet: www.nice.org.uk/page.aspx?o=TA064guidance Pacchiarotti A, Sbracia M, Frega A, Selman H, Rinaldi L, Pacchiarotti A (2010): Urinary hMG
(Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial. Fertil Steril 94: 2467–2469
Perales-Puchalt A, Legro RS (2013): Ovulation induction in women with polycystic ovary syndrome. Steroids 78: 767–772
Striegel H, Simon P (2007): Doping: High-Tech-Betrug im Sport. Internist: 48: 737–742
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2013): Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97: 1589–1597
van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2011): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011 Feb 16; 2: CD005354 van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG (2012): Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update 18: 111
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2015). Hypophysen- und Hypothalamushormone. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2015. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47186-9_27
Download citation
DOI: https://doi.org/10.1007/978-3-662-47186-9_27
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-47185-2
Online ISBN: 978-3-662-47186-9
eBook Packages: Medicine (German Language)